Opca Bolnica Varazdin

At Opca Bolnica Varazdin the Neurology department collaborates on studies that target heart health, focusing on conditions such as chronic heart failure and the primary prevention of atherosclerotic events. Researchers are evaluating novel agents that may reduce cardiovascular mortality and improve functional status.

• Chronic heart failure management
• Primary prevention of ASCVD
• Iron deficiency in symptomatic heart failure

These investigations aim to enhance treatment options for patients at risk of heart disease and to explore strategies that lower the burden of cardiovascular complications.

Clinical work at the site includes research on metabolic hormone disorders, especially those linked to overweight, obesity, and type 2 diabetes. Studies are testing therapies that influence insulin sensitivity and weight regulation.

• Obesity and weight management
• Type 2 diabetes glycemic control
• Metabolic hormone modulation

The goal is to identify safe and effective approaches that improve metabolic health and reduce the long‑term complications of hormonal imbalance.

Researchers are exploring immune‑mediated conditions, particularly multiple sclerosis, by assessing therapies that modulate B‑cell activity and inflammatory pathways.

• Relapsing multiple sclerosis
• Primary progressive multiple sclerosis
• Secondary progressive multiple sclerosis

The studies seek to demonstrate improved disease control, fewer relapses, and slowed disability progression for patients living with these autoimmune disorders.

Although the primary focus is neurology, the site contributes to musculoskeletal research by investigating neuro‑inflammatory mechanisms that affect motor function and muscle health in multiple sclerosis.

• Motor disability in MS
• Neuro‑inflammation and muscle tone
• Functional outcomes in progressive disease

These projects aim to preserve mobility and quality of life for individuals with chronic musculoskeletal involvement.

The Neurology department leads a robust portfolio of trials addressing a range of neurological conditions, from multiple sclerosis to agitation associated with Alzheimer’s disease.

• Relapsing‑remitting MS therapies
• Progressive MS interventions
• Agitation in Alzheimer’s disease

By testing new medicines and assessing long‑term safety, researchers aim to slow disease progression, reduce relapse rates, and improve behavioral symptoms in dementia.

Ongoing studies evaluate how targeted treatments can modify blood‑sugar levels and promote weight loss in patients with type 2 diabetes and obesity.

• HbA1c reduction strategies
• Weight management in diabetic cohorts
• Combination therapy with metformin

The purpose is to provide evidence for therapies that achieve better metabolic control and support sustainable lifestyle changes.

The facility conducts trials on severe, uncontrolled asthma, testing inhaled agents that aim to improve lung function and reduce exacerbations.

• Moderate‑to‑severe asthma treatment
• Bronchodilator efficacy
• Patient‑reported symptom improvement

These investigations focus on delivering more effective respiratory care for individuals whose asthma remains uncontrolled by standard therapy.

A dedicated program examines agitation in Alzheimer’s disease, using a novel combination therapy to assess behavioral outcomes and safety.

• Agitation management in AD
• Behavioral assessment scales
• Long‑term tolerability of neuropsychiatric agents

The aim is to provide clinicians with evidence‑based options that can reduce distressing symptoms and improve caregiver experience.